Additional file 1 of Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy

Abstract

Additional file 1: Table S1. Summary of application of Meet-URO score in mRCC patients receiving systemic therapies